With the development of China's national strength and the overall improvement of medical standards, China's life expectancy continues to rise. The demand for healthcare is increasing, and China's policies for managing medical supplies are becoming increasingly strict. The extensive and empirical traditional supply chain management model for medical supplies can no longer meet current needs. The pursuit of a lean supply chain management system (Supply Processing & Distribution, SPD) is becoming increasingly favored by the market.SPDIt can not only solve problems such as the inefficiency and complexity of traditional supply chain ordering models, the difficulty in managing materials within hospitals, and the numerous risks in the medical supervision process, but also serve upstream and downstream industries, empowering markets, finance, and other sectors comprehensively. In recent years, against the backdrop of pursuing high-quality development and driven by the development of software and hardware technology in China, SPD has become a key tool for medical institutions to achieve digitalization, refinement, and modernization, with the industry growing at a rapid pace.
Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') is preparing to write a 'Blue Book on the Current Situation and Development Trends of the Healthcare Supply Chain (SPD) Industry'. The aim is to deeply explore the development background of the SPD industry, analyze its historical development and typical models of foreign enterprises, as well as their significance for the development of China's SPD industry. Furthermore, the book will analyze China's SPD industry's technical barriers, industrial chain, current development status, and commercialization models, track future development trends of the industry, tap into the huge potential of industry development, and analyze the driving factors behind market development.
The Life Sciences Practice Group of Frost & Sullivan cordially invites enterprises in the SPD field to participate in the Blue Book, to jointly discuss the development direction and prospects of the SPD industry.
Frost & Sullivan will officially release the 'Blue Book on the Current Situation and Development Trends of the Medical Supply Chain (SPD) Industry' at the '18th Frost & Sullivan China Growth, Innovation and Leadership Summit & 3rd New Investment Conference' Life Sciences New Investment Summit Forum to be held in Shanghai from August 28th to August 29th, 2024. The book will be simultaneously pushed on Frost & Sullivan's official media and multiple media platforms, and we look forward to more cooperation and support from enterprises in various fields.
1
Research content
1) The Blue Book will provide a systematic introduction to the SPD industry, elaborating on its development history and opportunities; it will analyze the traditional medical supplies supply chain management model and the SPD management model, highlighting the multiple advantages that SPD has over traditional medical supplies management models, including scientific supplier ordering, efficient hospital material management, traceable government supervision, and mutual benefit with financial institutions. It will also delve into the driving factors for the development of the Chinese SPD industry.
2) The practical application of SPD in Japan has matured. The Blue Book will conduct an in-depth analysis of typical international SPD enterprise development models, represented by Japan, and elaborate on their main business operation models. It will also analyze and present representative companies that specialize in providing SPD services and those that provide SPD services through medical device distributors respectively.
3) The Chinese SPD industry faces high barriers in terms of capital investment, personnel requirements, system configuration, and resource demands. A comprehensive analysis is conducted on the entire industry chain, from upstream to downstream. In-depth discussions are held on the current status, service models, and business models of the Chinese SPD industry. Opportunities and challenges in the SPD industry are explored to a depth, presenting an all-round overview of the current development status and future trends of the Chinese SPD industry, highlighting the huge potential of the Chinese SPD market.
4) There are already many companies competing in the SPD industry. The Blue Book will sort out and present the current competitive landscape of the SPD industry, focusing on the business layout, strategic planning, and digital intelligence progress of major enterprises in the field. It will explore with the industry the latest development trends and competitive landscape dynamics.
2
Participation value
1) The 'Blue Book on the Current Situation and Development Trends of the Healthcare Supply Chain (SPD) Industry' will be simultaneously released on Frost & Sullivan's official account and multiple media platforms, sharing industry and corporate progress, highlighting differentiated features of enterprises, and enhancing their visibility in the capital market;
2) Cover hundreds of millions of customers, seamlessly integrating media, funds, banking, and brokerage communication channels. With over 5,000 high-quality media resources, effective deployment and promotion strategies can be carried out with precise placement;
3) Based on a mature industry analysis model, covering the core elements of market analysis, presenting a comprehensive and in-depth understanding of the industry, disseminating new concepts, and jointly exploring value enhancement paths with SPD enterprises;
The 4) New Investment Summit Forum on Life Sciences will gather industry leaders, biopharmaceutical companies, medical device companies, investment institutions, and professional service providers. With the theme of 'Adapting to Changes and Opening Up New Horizons', it will focus on new quality productivity and new opportunities, delve into new trends in global innovation and development, share the internationalization strategies of Chinese life science companies, and discuss new models for investment cooperation. The 'Blue Book on the Current Situation and Development Trends of the Medical Supply Chain (SPD) Industry' will be released at the medical device session of the New Investment Summit Forum on Life Sciences, sharing industry perspectives, promoting knowledge sharing and best practice exchanges within the industry, providing a platform for participating companies to showcase their technical strength, market strategies, and business advantages, and deepening the corporate image.
3
For cooperation, please contact us.
Knowledge Center, Life Sciences Business Unit, Frost & Sullivan
Email: HCknowledgecenter@frostchina.com
Li Qian, Consulting Director of Life Sciences Business Unit, Frost & Sullivan Greater China Region
Email: qian.li@frostchina.com
Project Manager, Life Sciences Business Unit, Frost & Sullivan Greater China Region, Wang Peng
Email: aaron.wang@frostchina.com
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and the cross-industry business development platform in Greater China, the Life Sciences Practice of Frost & Sullivan has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice of Frost & Sullivan has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating extensive project experience in various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
